# K-924 Phase III Confirmatory Study

Study · id `cardio:ct-nct04289649` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04289649](<https://clinicaltrials.gov/study/NCT04289649>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04289649

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 293 participants.

## Technical summary

Registry record NCT04289649. Randomized; triple masking; primary purpose treatment. Start 2020-04-02 (actual); primary completion 2020-11-21 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 293 participants (enrolled count; ClinicalTrials.gov record NCT04289649, source copy `cardio:ctgov-nct04289649-2023-11-29`, retrieved 2026-10-31)
- Started: 2020-04-02 (actual) (ClinicalTrials.gov record NCT04289649, source copy `cardio:ctgov-nct04289649-2023-11-29`, retrieved 2026-10-31)
- Primary completion: 2020-11-21 (actual) (ClinicalTrials.gov record NCT04289649, source copy `cardio:ctgov-nct04289649-2023-11-29`, retrieved 2026-10-31)
- Completion: 2020-11-21 (actual) (ClinicalTrials.gov record NCT04289649, source copy `cardio:ctgov-nct04289649-2023-11-29`, retrieved 2026-10-31)
- Countries: Japan (ClinicalTrials.gov record NCT04289649, source copy `cardio:ctgov-nct04289649-2023-11-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04289649-2023-11-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: K-924 Phase III Confirmatory Study
- Condition: Hypercholesterolemia
- Intervention (Drug): K-924 LD
- Intervention (Drug): K-924 HD
- Intervention (Drug): K-924 LD Placebo
- Intervention (Drug): K-924 HD Placebo
- Lead sponsor: Kowa Company, Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Kowa Company, Ltd. (`cardio:org-kowa-company-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial (`cardio:pubmed-36908150`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 71247c3162b3e31488dc226607fd5cc1a1456208c0d80c9079df2280c30b16bf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
